Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

FranceBack to France

Clinical trials in Corbeil Essonnes – page 191

3 332 clinical trials in Corbeil Essonnes, France across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

FranceOur site in FranceEssaisCliniques.fr(opens in a new tab)
Corbeil Essonnes at a glance
3 332
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

3 332 trials in Corbeil Essonnes

Open in trial search

Triple negative breast cancer+1

Not recruiting

Study on the Effects of Atezolizumab, Trastuzumab, and Pertuzumab in Patients with Early-Stage Triple-Negative or HER2+ Breast Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:Institut Gustave Roussy

Chronic myelomonocytic leukaemia

Not recruiting

Study on the Safety and Effectiveness of Azacitidine and Venetoclax for Patients with Higher-Risk Chronic Myelomonocytic Leukemia (CMML)

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Azacitidine
  • Sponsor:Groupe Francophone Des Myelodysplasies

Glioblastoma multiforme

Not recruiting

Study of Berubicin versus lomustine in adult patients with recurrent Glioblastoma Multiforme after first-line treatment failure

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Lomustine
  • Sponsor:Cns Pharmaceuticals Inc.

Familial hypertriglyceridaemia

Not recruiting

Study on the Effects of ARO-APOC3 for Adults with Familial Chylomicronemia Syndrome

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Sponsor:Arrowhead Pharmaceuticals Inc.

Colorectal cancer metastatic

Not recruiting

Study on Personalized Treatment for Metastatic Colorectal Cancer Using Regorafenib for Patients with Advanced Disease

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years
  • Substances:Regorafenib
  • Sponsor:Centre Hospitalier Universitaire De Rennes

Neoplasm

Not recruiting

Study of Vusolimogene Oderparepvec and Nivolumab for Patients with Solid Tumors

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Nivolumab
  • Sponsor:Replimune Inc.

Malignant melanoma

Not recruiting

Study of MaaT013 (Fecal Transplantation) Combined with Ipilimumab and Nivolumab in Patients with Previously Untreated Melanoma

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Sponsor:Assistance Publique Hopitaux De Paris

Colorectal cancer metastatic+1

Not recruiting

Study Comparing Avelumab and Standard Chemotherapy for Patients with Metastatic Colorectal Cancer with Microsatellite Instability

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Aflibercept
  • Sponsor:Fondation Franc.Cancerologie Digestive

Ovarian cancer recurrent

Not recruiting

Study of Avutometinib and Defactinib for Patients with Recurrent Low-Grade Serous Ovarian Cancer

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Avutometinib
  • Sponsor:Verastem Inc.

Ornithine transcarbamoylase deficiency

Not recruiting

Study of Avalotcagene Ontaparvovec for Patients Aged 12 and Older with Late-onset Ornithine Transcarbamylase Deficiency

Registered drug
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Prednisolone
  • Sponsor:Ultragenyx Pharmaceutical Inc.

Malignant melanoma

Not recruiting

Study on Fianlimab and Cemiplimab for Adults with Resectable Stage III and IV Melanoma

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Cemiplimab
  • Sponsor:Regeneron Pharmaceuticals Inc.

EGFR gene mutation+1

Not recruiting

Study on the Effectiveness and Safety of BAY 2927088 Compared to Standard Treatment in Patients with Advanced Non-Small Cell Lung Cancer with HER2 Mutations

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Bayer AG

Other cities in France

The busiest research cities in the country

All 366 cities in France

Clinical research in Corbeil Essonnes

What the registry says about research in the country

01 Diabetes and Metabolic Disorders

Clinical research focusing on novel treatments for Type 1 and Type 2 Diabetes, particularly investigating therapies like tirzepatide for glycemic control and cardiovascular outcomes in patients with obesity and diabetes.

  • Glycemic Control Studies
  • Cardiovascular Risk Management
  • Weight Management Therapies
02 Hematologic Malignancies

Groundbreaking trials in Multiple Myeloma treatment, evaluating combinations of targeted therapies including elranatamab, lenalidomide, and daratumumab for newly diagnosed and relapsed cases.

  • Novel Drug Combinations
  • Maintenance Therapy Optimization
  • Minimal Residual Disease Studies
03 Inflammatory and Autoimmune Conditions

Research examining innovative treatments for Immune Thrombocytopenia, Polymyalgia Rheumatica, and Lupus Nephritis, focusing on targeted therapies and steroid-sparing approaches.

  • Immunotherapy Development
  • Alternative Treatment Strategies
  • Disease Management Protocols
Back to FranceAll countries
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.